Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Konstantin Yenkoyan: Are We Targeting Alzheimer’s Disease at the Right Time and in the Right Place?
Konstantin Yenkoyan/LinkedIn
Apr 20, 2026, 01:13

Konstantin Yenkoyan: Are We Targeting Alzheimer’s Disease at the Right Time and in the Right Place?

Konstantin Yenkoyan, Scientist in Chief at Cobrain Center, Vice Rector for science at Yerevan State Medical University named after Mkhitar Heratsi, shared a post on LinkedIn:

“Weekend Scientific Digest. Are we targeting Alzheimer’s disease at the right time and in the right place?

A recent synthesis from April 16 Cochrane reports that anti-amyloid therapies show no clinically meaningful effect.

This is not a failure, it is a signal.

The key question is shifting, not only what to target, but:

  • When we intervene
  • Where within the disease cascade we act

What does this imply?

  • Intervention may come too late – pathology begins decades earlier
  • Amyloid alone may be insufficient – disease is multi-layered
  • Tau, synaptic and network dysfunction may be closer to clinical reality
  • Enhancing endogenous clearance pathways may be critical

And most importantly:

  • Early treatment requires trusted biomarkers
  • Clinical success requires meaningful outcomes

In Alzheimer’s disease, the challenge is no longer only how to treat, but when, and where, to intervene.”

Konstantin Yenkoyan

Stay updated on all scientific advances with Hemostasis Today.

Alzheimer’s Disease Cochrane reports Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine
NewsFeed